DGAP-News

Nanotech Systems Inc.: Appointment of Dr. David Scratchley as Chief Executive Officer

DGAP-News: Nanotech Systems Inc. / Key word(s): Change of Personnel
Nanotech Systems Inc.: Appointment of Dr. David Scratchley as Chief
Executive Officer

25.03.2011 / 12:30

---

SEATTLE, Washington, March 24, 2011, Nanotech Systems Inc. announces the
appointment of Dr. David Scratchley as Chief Executive Officer of the
company effective March 19, 2011. Catherine Soncrant has stepped down from
the CEO position and into the VP of Marketing effective immediately. As Ms.
Soncrant stated ´As the company begins to mature and is positioned to
evolve from a research and development organization into a true production
company, it was important that our senior leadership have the background
and understanding of the clinical trial process on a global scale and Dr.
Scratchley brings tremendous experience and understanding to guide us in
the right direction.´

With nearly 20 years´ experience in directing clinical research and the
operations of a Clinical Trial Network, comprised of clinical, data,
statistical, financial, quality assurance, and investigational pharmacy
services, Dr. Scratchley has conducted Phase I, II, and III trials in over
seventy medical school hospital clinics. As the Director of Operations for
Seattle Children´s Hospital, he ran the clinical trial network and built a
platform of knowledge in introducing new pharma products and technologies.
Prior to this Dr. Scratchley served on the faculty at Seattle University
and served as a Project Director at Axio Research.

According to Dr. Scratchley, ´I am truly excited to work with the team and
resources that Nanotech has worked diligently in building and to
participate in revolutionizing drug delivery systems in the field of
diabetes treatment is an opportunity to change the face of medicine and
treatment. Leading Nanotech, I am committed to exploring our global
partners in developing technology for market. I am honored to be part of
this organization and to work with our brethren in Europe to continue to
evolve our business.´

About Nanotech Systems, Inc.

Nanotech Systems, Inc. (FWB: N95) is a materials science company developing
unique and proprietary processes for delivery of pharmaceutical products
intra body with reactive qualities and efficiencies to affect the diseased
or compromised cells. With applications to medicine and physiology,
Nanotech Systems is developing materials and devices designed to interact
with the body at a subcellular scale with a high degree of specificity.
Nanotech Systems targets cellular and tissue specific clinical applications
designed to achieve maximal therapeutic affect with minimal side effects.
Nanotech uses its broad intellectual property rights and proprietary
know-how to establish application trials and testing for commercial
application at both the academic and corporate level with programs
throughout the U.S. and Canada and expansion into Europe.

For more information, please visit www.nano-techgroup.com.

This press release is for informational purposes only and does not
constitute, or form part of an offer to buy of the solicitation of any
offer to sell any securities in any jurisdiction not shall it (or any part
of it), or the fact of its distribution, form the basis of or be relied on
in connection with any contract therefore.

End of Corporate News

---

25.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

117045 25.03.2011